Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2008; 100(01): 151-153
DOI: 10.1160/TH08-02-0089
DOI: 10.1160/TH08-02-0089
Case Report
Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab
Authors
Further Information
Publication History
Received
15 February 2008
Accepted after major revision
27 April 2008
Publication Date:
22 November 2017 (online)
* Both authors contributed equally.
-
References
- 1 Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005; 106: 11-17.
- 2 Rizvi MA, Vesely SK, George JN. et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000; 40: 896-901.
- 3 Rock GA, Shumak KH, Buskard NA. et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. CanadianApheresis Study Group. N Engl J Med 1991; 325: 393-397.
- 4 Tsai HM, Raoufi M, Zhou W. et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 95: 886-892.
- 5 Cataland SR, Wu HM. Immunotherapy for thrombotic thrombocytopenic purpura. Curr Opin Hematol 2005; 12: 359-363.
- 6 Heidel F, Lipka DB, von Auer C. et al. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007; 97: 228-233.
- 7 George JN, Woodson RD, Kiss JE. et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006; 21: 49-56.
- 8 Franchini M, Veneri D, Lippi G. et al. The efficacy of rituximab in the treatment of inhibitor-associated he-mostatic disorders. Thromb Haemost 2006; 96: 119-125.
- 9 Scully M, Cohen H, Cavenagh J. et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136: 451-461.
- 10 Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 06: 394-403.
- 11 Ferrari S, Scheiflinger F, Rieger M. et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig iso-type, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectableADAMTS 13 activity. Blood 2007; 109: 2815-2822.
- 12 Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura?. J Clin Apher 2007; 22: 21-25.
- 13 Hauser SL, Waubant E, Arnold DL. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
- 14 McFarland HF. The B cell--old player, new position on the team. N Engl J Med 2008; 358: 664-665.
- 15 Stasi R, Cooper N, Del Poeta G. et al. Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood. 2008 prepub online doi:10.1182/blood-2007-12-129262..
- 16 George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935.